Glioblastoma (GBM) is a fatal brain tumour that is traditionally diagnosed based on
histological features. Recent molecular profiling studies have reshaped the World Health …

Targeted therapies, including small molecule inhibitors directed against aberrant kinase
signaling and chromatin regulators, are emerging treatment options for high-grade gliomas …

Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To
investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure …

DNA methylation is crucial for chromatin structure and gene expression and its aberrancies,
including the global “hypomethylator phenotype”, are associated with cancer. Here we show …

Background Glioblastoma (GBM) brain tumors lacking IDH1 mutations (IDHwt) have the
worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but …

Glioma is a common malignant brain tumor with great heterogeneity and huge difference in
clinical outcomes. Although lymphotoxin (LT) beta receptor (LTBR) has been linked to …

The effectiveness of tumor therapy, especially immunotherapy and oncolytic virotherapy,
critically depends on the activity of the host immune cells. However, various local and …

Simple Summary Glioma is one of the most common primary central nervous system (CNS)
tumors, and its molecular diagnosis is crucial. However, surgical resection or biopsy is risky …

Severe tumor heterogeneity drives the aggressive and treatment refractory nature of
glioblastomas (GBMs). While limiting GBM heterogeneity offers promising therapeutic …

Purposes To identify potent DNA methylation candidates that could predict response to
temozolomide (TMZ) in glioblastomas (GBMs) that do not have glioma‐CpGs island …